Get the Stockscreener App
3.41
2.10%
0.07
Turn Therapeutics Inc stock is traded at $3.41, with a volume of 4,057.
It is up +2.10% in the last 24 hours and down -2.01% over the past month.
Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.
See More
Previous Close:
$3.34
Open:
$3.48
24h Volume:
4,057
Relative Volume:
0.11
Market Cap:
$100.41M
Revenue:
-
Net Income/Loss:
$-1.77M
P/E Ratio:
-25.76
EPS:
-0.1324
Net Cash Flow:
$-1.46M
1W Performance:
-2.01%
1M Performance:
-2.01%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$3.41
$3.48
1-Week Range:
$3.20
$3.48
52-Week Range:
$2.5701
$26.50
Turn Therapeutics Inc Stock (TTRX) Company Profile
Name
Turn Therapeutics Inc
Sector
Industry
Phone
(818) 564-4011
Address
250 NORTH WESTLAKE BLVD., WESTLAKE VILLAGE
Compare TTRX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TTRX
Turn Therapeutics Inc
|
3.41 | 100.41M | 0 | -1.77M | -1.46M | -0.1324 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Turn Therapeutics Inc Stock (TTRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-29-25 | Initiated | D. Boral Capital | Buy |
Turn Therapeutics Inc Stock (TTRX) Latest News
Turn Therapeutics secures up to $25M in financing from Avenue Capital Group - MSN
D. Boral Capital Reaffirms Buy Rating for Turn Therapeutics (NASDAQ:TTRX) - MarketBeat
TTRX Maintains 'Buy' Rating with $8.00 Price TargetLatest Analyst Insights | TTRX Stock News - GuruFocus
Turn Therapeutics Secures Up to $25 Million Financing from Avenue Capital to Advance Atopic Dermatitis and Onychomycosis Programs - Minichart
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group - pharmiweb.com
Turn Therapeutics Secures Growth Capital to Advance Dermatology - TipRanks
Turn Therapeutics Secures Up To $25 Million Term Loan Facility From Avenue Venture Opportunities - TradingView
Turn Therapeutics (Nasdaq: TTRX) secures up to $25M loan facility - Stock Titan
Turn Therapeutics secures $25M loan facility from Avenue Capital By Investing.com - Investing.com Canada
Turn Therapeutics, Inc. Secures Up to $25 Million in Financing from Avenue Capital Group - marketscreener.com
Turn Therapeutics Inc. announced that it expects to receive $25 million in funding from Avenue Capital Management II, L.P. - marketscreener.com
Turn Therapeutics Inc. (TTRX) AI-Powered Stock Analysis - Meyka
Turn Therapeutics (TTRX) Stock Forecast and Price Target 2026 $TTRX - MarketBeat
Turn Therapeutics (TTRX) Stock Analysis Report | Financials & Insights - Benzinga España
TTRX: Phase II eczema trial for a novel IL-36/IL-31 inhibitor expects key data in Q2 2026 - TradingView
Turn Therapeutics Talks GX-03 Phase II Eczema Data Timeline and Non-Systemic Topical Strategy - MarketBeat
TTRX: Lead topical for eczema in phase II, with phase III trials planned and strong safety data - TradingView
Atara jumps amid report on FDA’s U-turn on cell therapy - Seeking Alpha
Technical Analysis of Turn Therapeutics Inc. (NASDAQ:TTRX) - TradingView
Turn Therapeutics Appoints Robert Redfield as Senior Advisor - TipRanks
Turn appoints Dr. Robert Redfield as senior advisor to guide GX-03 regulatory and clinical strategy - TradingView
Former CDC director joins Turn Therapeutics (TTRX) as senior health policy advisor - Stock Titan
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs - Caledonian Record
How much upside does Compass Therapeutics Inc. haveWall Street Watch & Daily Stock Momentum Reports - mfd.ru
What is the next catalyst for Palvella Therapeutics Inc.July 2025 Spike Watch & Consistent Return Investment Signals - mfd.ru
TTRX Should I Buy - Intellectia AI
Turn Therapeutics Inc.Common Stock (Nasdaq:TTRX) Stock Quote - FinancialContent
Will Ovid Therapeutics Inc. announce a stock splitQuarterly Market Review & Detailed Earnings Play Strategies - mfd.ru
Can Xilio Therapeutics Inc. expand into new marketsDollar Strength & Entry Point Confirmation Signals - mfd.ru
Aug Sentiment: What is the fair value of Candel Therapeutics Inc. stock nowJuly 2025 Reactions & Weekly Top Stock Performers List - mfd.ru
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences - BioSpace
Turn Therapeutics Highlights GX-03 Progress at Investor Conferences - TipRanks
Turn Therapeutics Inc Announces Presentations at Healthcare Conferences - TradingView
Will Turn Therapeutics Turn The Corner In 2026? - RTTNews
Positive Signs As Multiple Insiders Buy Turn Therapeutics Stock - Yahoo Finance
Analyzing Turn Therapeutics (TTRX) & The Competition - Defense World
TTRX Forecast — Price Prediction for 2026. Should I Buy TTRX? - Intellectia AI
When Will Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Turn A Profit? - Yahoo Finance
Turn Therapeutics Advances GX-03 Eczema Trial, Opening a New Catalyst for Investors - TipRanks
Reviewing Turn Therapeutics (TTRX) and Its Peers - Defense World
Turn Therapeutics' (TTRX) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Turn Therapeutics (TTRX) vs. Its Peers Head to Head Survey - Defense World
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Turn Therapeutics advances atopic dermatitis trial, expands pipeline By Investing.com - Investing.com Nigeria
Speculative Buy on Turn Therapeutics: Proprietary Platform, Capital-Efficient Growth, and 2026 Milestones as Key Upside Catalysts - TipRanks
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference - BioSpace
Turn Therapeutics advances atopic dermatitis trial, expands pipeline - Investing.com
Turn Therapeutics Issues Corporate, Pipeline and Financial Updates - TipRanks
Turn Therapeutics Inc Announces Corporate and Pipeline Updates for 2026 - TradingView — Track All Markets
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44 - Business Wire
Financial Review: Turn Therapeutics (TTRX) & Its Peers - Defense World
Turn Therapeutics Inc Stock (TTRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):